1. Home
  2. KOS vs TRAX Comparison

KOS vs TRAX Comparison

Compare KOS & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kosmos Energy Ltd. (DE)

KOS

Kosmos Energy Ltd. (DE)

N/A

Current Price

$2.15

Market Cap

1.7B

Sector

Energy

ML Signal

N/A

TRAX

First Tracks Biotherapeutics Inc. Ordinary Shares

N/A

Current Price

$51.71

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KOS
TRAX
Founded
2003
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
2011
2026

Fundamental Metrics

Financial Performance
Metric
KOS
TRAX
Price
$2.15
$51.71
Analyst Decision
Hold
Strong Buy
Analyst Count
13
12
Target Price
$3.12
★ $75.17
AVG Volume (30 Days)
★ 15.9M
776.1K
Earning Date
11-02-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $1,288,352,000.00
N/A
Revenue This Year
$39.59
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.84
$15.69
52 Week High
$3.34
$54.78

Technical Indicators

Market Signals
Indicator
KOS
TRAX
Relative Strength Index (RSI) 35.21 68.49
Support Level $1.92 $35.11
Resistance Level $3.08 N/A
Average True Range (ATR) 0.17 3.20
MACD -0.07 0.68
Stochastic Oscillator 17.86 74.05

Price Performance

Historical Comparison
KOS
TRAX

About KOS Kosmos Energy Ltd. (DE)

Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.

About TRAX First Tracks Biotherapeutics Inc. Ordinary Shares

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

Share on Social Networks: